EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phenethyl isothiocyanate and dasatinib combination synergistically reduces hepatocellular carcinoma growth via cell cycle arrest and oxeiptosis

Gabriele Strusi, Caterina M Suelzu, Nicole Horwood, Andrea E Münsterberg, Yongping Bao

Frontiers in Pharmacology · 04.10.2023 · 14

DOI: 10.3389/fphar.2023.1264032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.10.2023. Verfasst von Gabriele Strusi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, United Kingdom. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, which is among the most lethal tumours. Combination therapy exploits multiple drugs to target key pathways synergistically to reduce tumour growth. Isothiocyanates have been shown to possess anticancer potential and to complement the anticancer activity of other compounds. This study aimed to investigate the potential of phenethyl isothiocyanate (PEITC) to synergise with dasatinib, improving its anticancer potential in HCC.

Methods

MTT, 3D spheroids and clonogenic assays were used to assess the combination anti-tumour effect in vitro , whereas a murine syngeneic model was employed to evaluate the combination efficacy in vivo . DCFDA staining was employed to evaluate the production of reactive oxygen species (ROS), while flow cytometry and Western blot assays were used to elucidate the molecular mechanism of the synergistic activiy.

Results

PEITC and dasatinib combination exhibited a synergistic effect in vitro and in vivo . The combination induced DNA damage and oxidative stress through the production of ROS, which led to the formation of a premature CDK1/Cyclin B1 complex associated with induction of mitotic catastrophe. Furthermore, ROS activated oxeiptosis, a caspase-independent form of programmed cell death.

Conclusion

PEITC showed to enhance dasatinib action in treating HCC with increased production of ROS that induced cell cycle arrest followed by mitotic catastrophe, and to induce oxeiptosis. These results highlight the role that ITCs may have in cancer therapy as a complement of clinically approved chemotherapeutic drugs.

Schlagwörter

Stichwörter der Autor:innen

PEITCcancer therapeuticscombination therapydasatinibdrug developmentoncologyoxeiptosis

Autor:innen und Institutionen

  • Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, United Kingdom.
  • School of Biological Sciences, University of East Anglia, Norwich, United Kingdom.

Zitieren

APA

Strusi, G., Suelzu, C. M., Horwood, N., Münsterberg, A. E., & Bao, Y. (2023). Phenethyl isothiocyanate and dasatinib combination synergistically reduces hepatocellular carcinoma growth via cell cycle arrest and oxeiptosis. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1264032

Vancouver

Strusi G, Suelzu CM, Horwood N, Münsterberg AE, Bao Y. Phenethyl isothiocyanate and dasatinib combination synergistically reduces hepatocellular carcinoma growth via cell cycle arrest and oxeiptosis. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1264032

BibTeX
@article{Strusi2023,
  author = {Strusi, Gabriele and Suelzu, Caterina M and Horwood, Nicole and Münsterberg, Andrea E and Bao, Yongping},
  title = {Phenethyl isothiocyanate and dasatinib combination synergistically reduces hepatocellular carcinoma growth via cell cycle arrest and oxeiptosis},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1264032}
}
Kostenlos starten →